FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2480296027> ?p ?o ?g. }

• W2480296027 abstract "The Cadherin-6 (CDH6) gene was found to be frequently overexpressed in ovarian and renal cancers, while featuring a lineage-restricted normal tissue expression pattern. We hypothesized that based on the combined observation of frequent overexpression of CDH6 in cancer and a restricted normal tissue expression, CDH6 might be an ideal tumor antigen for targeting using an antibody-drug conjugate (ADC) approach. CHD6-ADC is a fully-human anti-CDH6 IgG1, linked via sulfo-SPDB to the tubulin-binding maytansinoid payload DM4. CDH6-ADC was evaluated across multiple linker-payload combinations with the sulfo-SPDB-DM4 format being selected based on a superior combined profile pertaining to activity, selectivity and tolerability. To gain a broader understanding of CDH6-ADC activity in vivo we profiled the lead candidate against a panel of 31 unselected patient derived ovarian xenograft (PDX) models in a 1×1×1 PDX clinical trial, similar to that described in Gao et al., 2015. In this unbiased high throughput in vivo screen, CDH6-ADC demonstrated robust antitumor activity, with an overall response rate of 39%. Responses were generally durable beyond 150 days and were achieved at doses yielding exposures anticipated to be achievable in humans and observed in PDX models featuring a range of CDH6 expression level and degree of tumor heterogeneity. Retrospective analysis of individual PDX responses and molecular profiling data demonstrate that sensitivity to CDH6-ADC is highly correlated to CDH6 transcript and protein levels. These findings suggest an ability to prospectively identify patients most likely to benefit from this novel targeted therapy. Furthermore, CDH6-ADC demonstrated robust tumor regressions in a representative PDX xenograft model that was refractory to carboplatin/paclitaxel standard of care therapy. These data suggest that CDH6-ADC may benefit both treatment naive patients and patients that have progressed on prior therapy containing tubulin-targeting anti-mitotics. Extending beyond ovarian cancer, we found CDH6 to be frequently overexpressed in renal cancer. CDH6-ADC was active against RCC PDX models featuring patient relevant levels of CDH6 expression. Data described herein suggest that this novel ADC may be an effective treatment for patients with CDH6 expressing tumors, including ovarian and renal cancer - both indications with a high unmet medical need. Citation Format: Carl U. Bialucha, Scott D. Collins, Yeonju Shim, Xiamei Zhang, Roberto Velazquez, Colleen Kowal, Caroline Bullock, Hongbo Cai, Stacy M. Rivera, Julie M. Goldovitz, Esther Kurth, Alice T. Loo, Guizhi Yang, John Green, Lance Ostrom, Matthew J. Meyer, Rebecca Mosher, Hui Gao, Juliet Williams, Emma Lees. In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 872." @default.
• W2480296027 created "2016-08-23" @default.
• W2480296027 creator A5006564877 @default.
• W2480296027 creator A5011776488 @default.
• W2480296027 creator A5013578775 @default.
• W2480296027 creator A5014008991 @default.
• W2480296027 creator A5022745113 @default.
• W2480296027 creator A5022940770 @default.
• W2480296027 creator A5022996406 @default.
• W2480296027 creator A5031002482 @default.
• W2480296027 creator A5036314552 @default.
• W2480296027 creator A5038059144 @default.
• W2480296027 creator A5042107018 @default.
• W2480296027 creator A5043647084 @default.
• W2480296027 creator A5060716064 @default.
• W2480296027 creator A5064989928 @default.
• W2480296027 creator A5065815396 @default.
• W2480296027 creator A5065952053 @default.
• W2480296027 creator A5070718217 @default.
• W2480296027 creator A5076836945 @default.
• W2480296027 creator A5080504219 @default.
• W2480296027 creator A5087697484 @default.
• W2480296027 date "2016-07-15" @default.
• W2480296027 modified "2023-10-15" @default.
• W2480296027 title "Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial" @default.
• W2480296027 doi "https://doi.org/10.1158/1538-7445.am2016-872" @default.
• W2480296027 hasPublicationYear "2016" @default.
• W2480296027 type Work @default.
• W2480296027 sameAs 2480296027 @default.
• W2480296027 citedByCount "0" @default.
• W2480296027 crossrefType "proceedings-article" @default.
• W2480296027 hasAuthorship W2480296027A5006564877 @default.
• W2480296027 hasAuthorship W2480296027A5011776488 @default.
• W2480296027 hasAuthorship W2480296027A5013578775 @default.
• W2480296027 hasAuthorship W2480296027A5014008991 @default.
• W2480296027 hasAuthorship W2480296027A5022745113 @default.
• W2480296027 hasAuthorship W2480296027A5022940770 @default.
• W2480296027 hasAuthorship W2480296027A5022996406 @default.
• W2480296027 hasAuthorship W2480296027A5031002482 @default.
• W2480296027 hasAuthorship W2480296027A5036314552 @default.
• W2480296027 hasAuthorship W2480296027A5038059144 @default.
• W2480296027 hasAuthorship W2480296027A5042107018 @default.
• W2480296027 hasAuthorship W2480296027A5043647084 @default.
• W2480296027 hasAuthorship W2480296027A5060716064 @default.
• W2480296027 hasAuthorship W2480296027A5064989928 @default.
• W2480296027 hasAuthorship W2480296027A5065815396 @default.
• W2480296027 hasAuthorship W2480296027A5065952053 @default.
• W2480296027 hasAuthorship W2480296027A5070718217 @default.
• W2480296027 hasAuthorship W2480296027A5076836945 @default.
• W2480296027 hasAuthorship W2480296027A5080504219 @default.
• W2480296027 hasAuthorship W2480296027A5087697484 @default.
• W2480296027 hasConcept C121608353 @default.
• W2480296027 hasConcept C126322002 @default.
• W2480296027 hasConcept C143998085 @default.
• W2480296027 hasConcept C159654299 @default.
• W2480296027 hasConcept C197934379 @default.
• W2480296027 hasConcept C203014093 @default.
• W2480296027 hasConcept C207001950 @default.
• W2480296027 hasConcept C2777325958 @default.
• W2480296027 hasConcept C2778375690 @default.
• W2480296027 hasConcept C2780427987 @default.
• W2480296027 hasConcept C2908647359 @default.
• W2480296027 hasConcept C502942594 @default.
• W2480296027 hasConcept C542903549 @default.
• W2480296027 hasConcept C54355233 @default.
• W2480296027 hasConcept C71924100 @default.
• W2480296027 hasConcept C86803240 @default.
• W2480296027 hasConcept C99454951 @default.
• W2480296027 hasConceptScore W2480296027C121608353 @default.
• W2480296027 hasConceptScore W2480296027C126322002 @default.
• W2480296027 hasConceptScore W2480296027C143998085 @default.
• W2480296027 hasConceptScore W2480296027C159654299 @default.
• W2480296027 hasConceptScore W2480296027C197934379 @default.
• W2480296027 hasConceptScore W2480296027C203014093 @default.
• W2480296027 hasConceptScore W2480296027C207001950 @default.
• W2480296027 hasConceptScore W2480296027C2777325958 @default.
• W2480296027 hasConceptScore W2480296027C2778375690 @default.
• W2480296027 hasConceptScore W2480296027C2780427987 @default.
• W2480296027 hasConceptScore W2480296027C2908647359 @default.
• W2480296027 hasConceptScore W2480296027C502942594 @default.
• W2480296027 hasConceptScore W2480296027C542903549 @default.
• W2480296027 hasConceptScore W2480296027C54355233 @default.
• W2480296027 hasConceptScore W2480296027C71924100 @default.
• W2480296027 hasConceptScore W2480296027C86803240 @default.
• W2480296027 hasConceptScore W2480296027C99454951 @default.
• W2480296027 hasLocation W24802960271 @default.
• W2480296027 hasOpenAccess W2480296027 @default.
• W2480296027 hasPrimaryLocation W24802960271 @default.
• W2480296027 hasRelatedWork W1437257107 @default.
• W2480296027 hasRelatedWork W1971104697 @default.
• W2480296027 hasRelatedWork W2006769811 @default.
• W2480296027 hasRelatedWork W2017589574 @default.
• W2480296027 hasRelatedWork W2033888421 @default.
• W2480296027 hasRelatedWork W2272190705 @default.
• W2480296027 hasRelatedWork W2397558680 @default.
• W2480296027 hasRelatedWork W2490607079 @default.
• W2480296027 hasRelatedWork W2500461060 @default.
• W2480296027 hasRelatedWork W2592222428 @default.
• W2480296027 hasRelatedWork W2594108931 @default.
• W2480296027 hasRelatedWork W2787296552 @default.

• next